is retatrutide banned by wada New Prohibited List enforced since January 1, 2026 – International Weightlifting Federation WADA Release 2020 Anti-Doping Prohibited
Description
Contact your trial team or GP promptly if you experience: Persistent or severe nausea, vomiting, or diarrhoea that prevents adequate fluid or food intake Signs of dehydration, such as dizziness, dark urine, or reduced urination Severe or persistent abdominal pain, which may rarely indicate pancreatitis a known risk with GLP-1 receptor agonist therapies or gallbladder problems [18] [21] Rapid or irregular heartbeat (palpitations) Significant injection site reactions, including signs of infection (redness, warmth, swelling, or discharge) Symptoms of low blood sugar (hypoglycaemia) if you are also taking insulin or a sulfonylurea, such as shakiness, sweating, or confusion If you are unsure whether your symptoms require urgent attention, contact NHS 111 (by phone or online at 111.nhs.uk) for advice
10.1093/jnci/djx012 19 CasesA
In an exploratory analysis of BMI subgroups, a reduction in heavy drinking days and total alcohol intake was found in individuals with a baseline BMI 30 kg/m 2 treated with exenatide, compared to the BMImatched placebo group (total n = 30)
Important Research Notice: Retatrutide is currently intended for clinical trial and laboratory research purposes only
Always follow specific storage instructions from your compounding pharmacy, as formulations may vary slightly in stability requirements
Sudden fiber increases combined with GLP-1's delayed gastric emptying may worsen nausea or bloating
